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Abstract
OBJECTIVE: To study the effects of a decoction of
Fuzhengzengxiao formula on lung adenocarcino-
ma regarding the inflammatory protein S100A9
known to enhance cancer cell sensitivity.
METHODS: A nude mouse model of human lung
adenocarcinoma was established. The mice were
randomly divided into four groups using the ran-
dom number table method: Group Ⅰ, control;
Group Ⅱ, treatment with a decoction of the Fu-
zhengzengxiao formula alone; Group Ⅲ, treatment
with radiotherapy alone; and Group Ⅳ, treatment
with radiotherapy plus a decoction of Fuzhengz-
engxiao formula. When the tumor body was 1 cm3
in diameter, the tumor bearing mice in GroupsⅢ and Ⅳ were irradiated at a single dose of 10
Gy and the tumor inhibition rate was evaluated.
The expression of S100A9 was determined using
Western blotting and q-PCR (Real-time Quantita-
tive PCR Detecting System). The sensitivity of
cells containing RNAi S100A9 to radiotherapy
was evaluated using the Click multiple target
model,and the cell cycle was analyzed using flow
cytometry.
RESULTS: Relative to the control group,the expres-
sion of S100A9 in the tumors in each treatment
group was decreased,especially in Group Ⅳ. The
sensitizing enhancement ratio (SER) Dq was >1 af-
ter RNAi S100A9; it decreased the surviving fraction
after a 2 Gy dose exposure,and also the D0 and Dq
of the tumor cells; in addition, the radiosensitivity
of G2/M cells was significantly increased.
CONCLUSION: The decoction of the Fuzhengz-
engxiao formula downregulated the expression of
S100A9 in lung adenocarcinoma cells.
© 2015 JTCM. All rights reserved.
Key words: Calgranulin B; RNA interference; Radia-
tion tolerance; Adenocarcinoma of lung; Fuzhengz-
engxiao formula
INTRODUCTION
Lung cancer is one of the most fatal tumors worldwide.
Eighty percent of non-small cell lung cancer patients
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have a metastasis rate of ≤ 70%; because of aging and
other associated diseases, most patients cannot tolerate
surgical treatment and consequently radiotherapy is
the main treatment method. However, the treatment
failure rate ranges from 60% to 70%.1-3 Previous studies
have reported that the Fuzhengzengxiao formula signif-
icantly improved the efficacy and reduced the side ef-
fects of radiotherapy in lung cancer patients; however,
the pathogenesis regarding its enhancement of the effi-
cacy of radiotherapy remains unclear. It has been found
that in mice that were treated with the Fuzhengzengx-
iao formula before irradiation, S100A9 expression in
tumor cells was obviously abnormal (when assayed us-
ing protein microarray technology), relative to mice
that received treatment with radiation alone. We hy-
pothesized that S100A9 may be involved in enhancing
tumor radiosensitivity after treatment with the Fu-
zhengzengxiao formula. The objective of the present
study was to investigate how S100A9 influenced can-
cer cell sensitivity to radiotherapy while the cancer was
being treated with a decoction of the Fuzhengzengxiao
formula.
MATERIALS ANDMETHODS
Drugs and reagents
The Fuzhengzengxiao formula is composed of
Huangqi (Radix Astragali Mongolici), Shihu (Herba
Dendrobii Nobilis), Beishashen (Radix Glehniae), Jinyi-
nhua (Flos Lonicerae), Honghua (Flos Carthami), Sumu
(Lignum sappan), Baizhu (Rhizoma Atractylodis Macro-
cephalae), Taizishen (Radix Pseudostellariae), Gouqizi
(Fructus Lycii), Jixueteng (Caulis Spatholobi), Fuling
(Poria) and Jineijin (Endothelium Coreneum Gigeriae
Galli), which were decocted twice. The decoctions
were mixed and concentrated into 2.2 g of crude drugs/
mL, and then disinfected by boiling. RNAi S100A9
was provided by Cyagen Biosciences Inc., (Guangzhou,
China); it was subcultured in RPMI1640 containing
10% fetal calf serum. Calf serum and diethyl pyrocar-
bonate (DEPC) were purchased from the Sigma Com-
pany (St. Louis, Missouri, USA). Rabbit anti-S100A9
antibody was purchased from the Proterintech Compa-
ny (Chicago, IL, USA ).
Animals and the PAa cell line
The experimental animals were 6-week-old male
BALB/C-nu/nu nude mice. They were purchased from
the Institute of Experimental Animals, Chinese Acade-
my of Medical Sciences, and raised in specified patho-
gen free conditions (certificate of quality No. SCXKJ
2009-004). The low transfer human pulmonary adeno-
carcinoma was purchased from the Pathological Sec-
tion of the Medical Department, Peking University
(Beijing, China).
Establishment of animal models
Pulmonary adenocarcinoma cells in the logarithmic
growth phase were taken. They were prepared at a con-
centration of 5 × 106 cells/mL with RPMI1640 culture
medium; 0. 3 mL of these cells was injected into the
armpit of the forelimb of each nude mouse. The
mouse were randomly divided into four groups (each
group have 28 nude mouse )using the random number
table method: Group Ⅰ, control; Group Ⅱ, treated
with the decoction of the Fuzhengzengxiao formula
alone; Group Ⅲ, treated with radiotherapy alone; and
Group Ⅳ, treated with radiotherapy plus the decoc-
tion of the Fuzhengzengxiao formula. From the day of
tumor inoculation, each nude mouse in Groups Ⅱ
and Ⅳ was intragastrically administered 0.5 mL (1.1 g
crude drug) of the decoction of the Fuzhengzengxiao
formula daily, and the other two groups were adminis-
tered an equal volume of distilled water. When the tu-
mor had reached a size of 1 cm3 (at about 28 days after
inoculation) the mouse in GroupsⅢ andⅣ were irra-
diated at a single dose of 10 Gy. In 18 nude mouse
from each group, the tumors were removed and ho-
mogenized at 6, 12 and 24 h after irradiation. Changes
in the tumor growth rate were monitored in the 10 re-
maining mouse in each group.
Tumor inhibition rate
To observe changes in tumor volume, this was mea-
sured 1 day before radiotherapy and every 2 days after
radiotherapy for a total of 10 times; mouse were killed
after the last measurement, and the weight of the tu-
mor was measured and the growth inhibition rate cal-
culated. The tumor inhibition rate = (C − T)/C ×
100%, where C is the mean weight of the tumors in
the negative control group, and T is the mean weight
of the tumors in a given experimental group.
Detection of S100A9 protein expression
First, 200 μL of protein lysate was added into a centri-
fuge tube holding 20 mg of tumor, which was homoge-
nated and placed on ice for 15 min, and centrifuged at
4 ℃ ( 9000 ×g for 10 min); the supernatant was draw
to determine the protein content. Protein loads were
20 μg/lane. It was separated using 12% separation gel
and 5% stacking gel. Then the protein was semi dryly
transferred to PVDF film, 8-mL anti-S100A9 was di-
luted using closed liquid (S100A9, 1∶500 dilution; ac-
tin, 1∶1500 dilution) and reacted at 4 ℃ overnight;
the second antibody (1∶10000) was reacted for 4 h.
The ECL chemiluminescence method, exposure to
X-rays and scanning film JX330 (Sharp Electronics, To-
kyo, Japan) involving a transmission scanner were used
for analysis. Finally, LabWorks software was used to
evaluate the image grayscale.
Detection of the mRNA expression of S100A9
Extraction of total RNA and first strand synthesis of
cDNA were carried out according to the instructions
of the manufacturer. Real time PCR was performed in
a 25 μL reaction system. It included: 10 μL of 2 ×
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SYBR mixture (Synergy Brands, TIANGEN) 1 μL
PCR forward primer (0 μM), 1 μL PCR reverse primer
(10 μM), 0. 3 μL Taq DNA polymerase and 25 μL
ddH2O. The forward primer was S100A9:5′-AGATG-
GAGCGCAGCATAACCACC-3′ . The reverse primer
was S100A9: 5′-GCTCAGGGTGTCAGGGT-
GTCCTT-3′ , and the length of the amplified product
was 80 bp. The PCR reaction was carried out in an
ABI 7500 PCR instrument. The amplification reaction
conditions for S100A9 were as follows: denaturation at
95 ℃ for 2 min and then denaturation for 20 s at
94 ℃; denaturation for 20 s at 59 ℃; denaturation for
30 s at 72℃; 40 cycles; and elongation at 72℃ for 30 s.
The mRNA expression of S100A9 was analyzed by the
2(-Delta Delta C[T]) method.
Colony forming experiment
Regarding the mice in the control group, the RNAi
S100A9 in PAa cells and the cell suspension was pre-
pared by centrifugation. For counting, cells were inocu-
lated into 25 cm2 cell culture bottles. The cell inocula-
tion numbers were 600, 1000, 4000, 8000 and 10
000, with medium supplied to 4 mL. There were three
groups: blank; control; and RNAi S100A9. Each group
was irradiated at single doses of 0, 2, 4, 6 and 8 Gy (us-
ing a 60Co device located in the Chemistry Department
of Beijing Normal University at a dose rate of 1 Gy/
min). Each group consisted of three parallel sets of ex-
perimental bottles. Cells were maintained in culture
medium until for 10 days after irradiation, and the me-
dium was changed every 3 days. Cells were fixed in
100% methanol, and stained using crystal violet. They
were then counted using a Gel-Pro Analyzer and the
number of surviving PAa cell clones were recorded af-
ter irradiation at different doses in the various treat-
ment groups (clones were counted when > 50 cells
were present). The radiation sensitivity of the cells con-
taining RNAi S100A9 was evaluated using the Click
multiple target model.
Determination of the phases of the cell cycle
The lung PAa cells were harvested in the logarithmic
growth phase, digested using pancreatic enzymes, and
suspended at a density of 1. 5 × 106/mL in 10% FCS+
RPMI1640 culture medium in culture bottles. Each
treatment group was irradiated at a single dose of 0 or
2 Gy after adherence and growth for 24 h. Each group
had three parallel experimental bottle sets. The cells
were collected after irradiation. They were centrifuged
at 1000 rpm for 8 min, the supernatant was discarded
and they were washed twice with PBS. Cells were fixed
in anhydrous ethanol for 12 h at 4 ℃ . They were fil-
tered using a 400 mesh nylon net, and then centri-
fuged. The supernatant was discarded and the cells
were mixed with 500 μL PBS, pulsed with 10-μl RNas-
eA (10 mg/mL) in a water bath at 37 ℃; 50-μL propid-
ium iodide was added before detection and staining in
the dark for 30 min at 4 ℃. The cell cycle phases were
determined using flow cytometry. Changes in the cell
cycle were analyzed using CELLQUEST software.
Statistical analysis
Quantitative data were expressed as the mean ± stan-
dard deviation ( xˉ ± s). One-way analysis of variance
and least significant difference-t were performed using
SPSS 10.0 software (SAS Institute, Chicago, IL, USA)
for the differences among the groups. A P-value <
0. 05 was considered as being statistically significant.
RESULTS
Tumor inhibition rate
The average tumor weight in the Group Ⅰ was (1. 82
± 0. 10) g, and the average tumor weight in Group Ⅱ
was (1.69 ± 0. 13) g; the tumor inhibition rate was 7.
2%. The average tumor weight in GroupⅢ was (1. 40
± 0. 15) g and the tumor inhibition rate was 22. 9%.
The average tumor weight in Group Ⅳ was (0. 83 ±
0. 12) g and the tumor inhibition rate was 54. 3%. Rel-
ative to Group Ⅱ, the tumor inhibition rate in GroupⅢ increased significantly (P < 0. 05). As compared
with the control group, the tumor inhibition rate in-
creased in GroupⅡ, but the difference was not signifi-
cant. Relative to all the other groups, the tumor inhibi-
tion rate in Group Ⅳ increased significantly (P <
0. 05) (Figure 1).
Protein and mRNA expression of S100A9
The Fuzhengzengxiao decoction increased sensitivity of
lung cancer cells to radiotherapy through down-regulat
ion of S100A9 protein and mRNA expression (Figures
2-4 ).
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Figure 1 Tumor inhibition rateⅠ: control group, treated intragastrically administrated
with 0. 5 mL distilled water; Ⅱ: Fuzhengzengxiao formula
group, treated intragastrically administrated with 0. 5 mL
(1.1 g crude drug) Fuzhengzengxiao formula; Ⅲ: simple ra-
diotherapy group, treated with radiated once 10 Gy dose
the tumor body was 1 cm3 in diameter; Ⅳ: radiotherapy
plus Fuzhengzengxiao formula group, treated intragastrical-
ly administrated with 0. 5 mL (1. 1 g crude drug) Fuzhengz-
engxiao formula and radiated once 10 Gy dose when the tu-
mor body was 1 cm3 in diameter. aP < 0. 05, compared with
control group; bP < 0. 05, compared with Fuzhengzengxiao
formula group; cP < 0. 05, compared with simple radiothera-
py group.
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Results of the colony forming assay
The surviving fraction after irradiation at a dose of 2
Gy (SF2Gy) was determined. By experiment the average
SF2Gya of the blank was 0. 401 ± 0. 064, the average
SF2Gya of the control was 0. 442 ± 0. 037 and the aver-
age SF2Gya of RNAi S100A9 was 0. 350 ± 0. 057. the ra-
diosensitivity of lung adenocarcinoma was increased af-
ter RNAi S100A9. (Table 1, Figure 5)
Cell cycle analysis using flow cytometry
Silence S100A9 expression increased the radiosensitivi-
ty of lung adenocarcinoma through G2/M cell cycle ar-
rest. (Tables 2, 3; Figures 6, 7).
Figure 2 Protein expression of S100A9 and actin at 6, 12 and 24 h after r radiotherapy
A: the protein expression of S100A9 and actin at 6 h after radiotherapy. B: the protein expression of S100A9 and actin at 12 h after
radiotherapy. C: the protein expression of S100A9 and actin at 24 h after radiotherapy. 1: control group was treated intragastrical-
ly administrated with 0.5 mL distilled water; 2: Fuzhengzengxiao formula group was treated intragastrically administrated with
0.5 mL (1.1 g crude drug) Fuzhengzengxiao formula; 3: simple radiotherapya group was treated with radiated once 10 Gy dose
the tumor body was 1 cm3 in diameter; 4: radiotherapy plus Fuzhengzengxiao formula group was treated intragastrically adminis-
trated with 0.5 mL (1.1 g crude drug) Fuzhengzengxiao formula and radiated once 10 Gy dose when the tumor body was 1 cm3 in
diameter.
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Figure 3 Protein expression of S100A9 at different time points after radiotherapyⅠ: control group, treated intragastrically administrated with 0. 5 mL distilled water;Ⅱ: Fuzhengzengxiao formula group, treated
intragastrically administrated with 0. 5 mL (1. 1 g crude drug) Fuzhengzengxiao formula;Ⅲ: simple radiotherapy group, treated
with radiated once 10 Gy dose the tumor body was 1 cm3 in diameter; Ⅳ: radiotherapy plus Fuzhengzengxiao formula group,
treated intragastrically administrated with 0. 5 mL (1.1 g crude drug) Fuzhengzengxiao formula and radiated once 10 Gy dose
when the tumor body was 1 cm3 in diameter. aP < 0. 05, compared with control group; bP < 0. 05, compared with Fuzhengzengx-
iao formula group; cP < 0. 05, compared with simple radiotherapy group.
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Figure 4 mRNA expression of S100A9 at different time points after radiotherapyⅠ: control group,treated intragastrically administrated with 0.5 mL distilled water;Ⅱ: Fuzhengzengxiao formula group, treated
intragastrically administrated with 0.5 mL (1. 1 g crude drug) Fuzhengzengxiao formula;Ⅲ: simple radiotherapya group, treated
with radiated once 10 Gy dose the tumor body was 1cm3 in diameter; Ⅳ: radiotherapy plus Fuzhengzengxiao formula group,
treated intragastrically administrated with 0.5 mL (1.1 g crude drug) Fuzhengzengxiao formula and radiated once 10 Gy dose
when the tumor body was 1 cm3 in diameter. aP < 0. 05, compared with control group; bP < 0. 05, compared with Fuzhengzengx-
iao formula group; cP < 0. 05, compared with simple radiotherapy group.
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DISCUSSION
S100A9 protein (calgranulin B, MRP14) belongs to
the S100 protein family; it is a calcium binding protein
related to trauma and tumor inflammation. Calcium
binding protein is an important medium in which cal-
cium ions are produced regarding physiological activi-
ty. S100A9 participates in multiple physiological pro-
cesses, such as the inflammatory response, mediation
of growth inhibition, and regulation of cell growth and
differentiation.4 Studies have shown that S100A8/
S100A9 positive inflammatory cells can be found in
malignant stromal epithelial tumors, such as skin,
colorectal and prostate tumors. Cell inflammation
plays an important role in tumor stroma; it can result
in the production of cytokines, growth hormones, in-
creased levels of active oxygen and nitric oxide, and
other factors. They are involved in promoting cell pro-
liferation, inhibition of apoptosis and can induce
changes in and damage to cell morphology, resulting in
tumorigenesis. 5-9 Abnormal expression of S100 protein
in malignant tumors has been reported to be closely as-
Group
Blank
Control
RNAi S100A9
n
3
3
3
N
2.677±0.934
2.930±0.499
2.228±0.560
D0 (Gy)
1.166±0.077
1.173±0.031
1.159±0.026
Dq (Gy)
1.088±0.210
1.246±0.075
0.902±0.141
SERDq
-
-
1.382±0.022
Table 1 Radiobiological parameter values obtained using Click multiple target model fitting ( xˉ ± s)
Notes: blank group: pulmonary adenocarcinoma cell group; control group: pulmonary adenocarcinoma cells from the RNAi control
group; RNAi S100A9 group: pulmonary adenocarcinoma cells from the RNAi S100A9 group. N: the extrapolation number, a parameter
used to measure the width of the shoulder of the survival curve; D0: the mean lethal dose; Dq: the quasi-threshold dose; SER: sensitization
enhancement ratio.
Group
Blank
Control
RNAi S100A9
n
3
3
3
G0/G1
49.9±0.4
51.3±3.0
52.9±2.6
S
38.9±0.9
38.8±3.4
35.0±2.0
G2/M
11.2±0.9
9.9±0.6
12. 1±0.6a
Notes: blank group: pulmonary adenocarcinoma cell group; control group: pulmonary adenocarcinoma cells from the RNAi control
group; RNAi S100A9 group: pulmonary adenocarcinoma cells from the RNAi S100A9 group. aP < 0. 05, compared with the control
group.
Table 2 Cell cycle analysis of non-irradiated blank, control and RNAiS1000A9 groups (%, xˉ ± s)
Figure 6 Cell cycle distribution of blank, control and RNAiS1000A9 groupswith non-irradiated
Blank group: pulmonary adenocarcinoma cell group; control group: pulmonary adenocarcinoma cells from the RNAi control
group; RNAi S100A9 group: pulmonary adenocarcinoma cells from the RNAi S100A9 group. aP < 0. 05, comparedwith the control
group.
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Figure 5 Cell survival curves for the Blank, Control and
S100A9 groups
Blank group: pulmonary adenocarcinoma cell group; con-
trol group: pulmonary adenocarcinoma cells from the RNAi
control group; RNAi S100A9 group: pulmonary adenocarci-
noma cells from the RNAi S100A9 group.
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sociated with staging and prognosis. 10Arai et al 11 evalu-
ated surgical specimens from 70 patients with lung ade-
nocarcinoma using immunohistochemistry and the re-
verse transcription polymerase chain reaction method;
it was found that S100A9 was highly expressed in lung
adenocarcinoma tissues, and that its expression had a
significant positive correlation with the degree of differ-
entiation of lung adenocarcinoma.
In the present study, we found that the radiation sensi-
tizing effect of Fuzhengzengxiao formula was related to
S100A9;12 we evaluated changes in S100A9 expression
in tumor cells after treatment with Fuzhengzengxiao
formula and irradiation. The expression of S100A9
was detected using Western blotting and q-PCR; it was
found that the expression of S100A9 was decreased.
With increasing time after irradiation there was a signif-
icant difference in the tumor inhibition rate between
the irradiated group and the control group (P < 0. 05);
this finding confirmed that S100A9 had a radiation
protection effect regarding lung adenocarcinoma cells.
In addition, with increasing time after irradiation, the
level S100A9 expression decreased, and thus the radia-
tion protection effect should gradually decrease result-
ing in enhancement of radiosensitivity. After irradia-
tion, the expression of S100A9 was significantly de-
creased (P < 0. 05) and the tumor inhibition rate in-
creased (P < 0. 05) in the group treated with Fuzhengz-
engxiao formula relative to the group that was not; this
confirmed that the Fuzhengzengxiao formula enhanced
tumor cell radiosensitization by inhibiting the expres-
sion of S100A9. The expression of S100A9 has been re-
ported to be downregulated in esophageal squamous
cell carcinoma, head and neck squamous cell cancer
and other epithelial tumors, and was positively correlat-
ed with the degree of tumor differentiation, suggesting
that S100A9 plays an important role in the pathogene-
sis of squamous cell carcinoma. 13,14 This may be related
to different mechanisms regarding S100A9 in different
tumors.
In the current study it was found that determining tu-
mor cell radiosensitivity in vitro was closely related to
the effects of clinical radiotherapy on the tumor.15 De-
termination of tumor cell radiosensitivity would con-
tribute to the formulation of more reasonable and effec-
tive radiotherapy plans in a clinical setting. Regarding
the parameters reflecting cell radiosensitivity, SF2, D0
and N are commonly used in evaluations. The higher
the values of SF2 and D0 the lower the radiosensitivity,
and the lower these values are the higher the radiosensi-
tivity. To further confirm that the level of expression of
S100A9 is related to the radiosensitivity of lung adeno-
carcinoma, we found using the colony formation assay
that the value of SF2was decreased after the administra-
tion of RNAi S100A9. In addition, colony survival
analysis showed that before and after RNAi S100A9 ad-
ministration the D0 was 1. 159 and 1. 112, respective-
ly, and the extrapolated values for N were 2. 228 and
2. 636, respectively; the SERDq was >1. Thus, compar-
ison of the values of SF2, D0 and N suggested that the
radiosensitivity of lung adenocarcinoma was enhanced
after RNAi S100A9 administration.
The resistance of tumor cells to radiotherapy is related
to cell radiosensitivity, repair of sublethal damage, redis-
tribution in the cell cycle, and the levels of oxygenation
and hypoxia. Tumor cells are often in different phases
of the cell cycle, and cell radiosensitivity varies greatly
Group
Blank
Control
RNAi S100A9
n
3
3
3
G0/G1
50.7±1.9
50.8±1.6
42.6±3.6ab
S
32.8±3.0
33.4±2.4
28.9±3.6
G2/M
16.9±1.4
16.5±1.1
28.5±0.9ab
Notes: blank group: pulmonary adenocarcinoma cell group; control group: pulmonary adenocarcinoma cells from the RNAi control
group; RNAi S100A9 group: pulmonary adenocarcinoma cells from the RNAi S100A9 group. aP < 0. 05, compared with the blank group;
bP < 0. 05, compared with the control group.
Table 3 Cell cycle analysis after irradiation at a dose of 2 Gy in the blank, control and RNAiS1000A9 groups (%, xˉ ± s)
Figure 7 Cell cycle distribution of the blank, control and RNAi S100A9 groups after irradiation at a dose of 2 Gy
Blank group: pulmonary adenocarcinoma cell group; control group: pulmonary adenocarcinoma cells from the RNAi control
group; RNAi S100A9 group: pulmonary adenocarcinoma cells from the RNAi S100A9 group. aP < 0. 05, compared with the blank
group; bP < 0. 05, compared with the control group .
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in these different phases. Among the cell cycle phases,
G2/M has highest radiosensitivity, followed by the Gl/
S phase, and the late S phase has strong radioresistance. 16
The study found that the SF2Gy of the tumor cell was
reduced by RNAi S100A9, and the SERDq was >1;
RNAi S100A9 increased the percentage of cells in the
G2/M phase, and further promoted tumor cells to en-
ter and arrest in the G2/M phase from the more radia-
tion resistant Gl/S phase after irradiation. Consequent-
ly, we considered that the Fuzhengzengxiao formula im-
proved the radiation sensitivity of tumor cells by lower-
ing the expression of S100A9 and raising the ratio of
cells arrested in the G2/M phase, thus improving the
efficacy of radiotherapy.
In conclusion, the decoction of the Fuzhengzengxiao
formula increased the sensitivity of lung cancer cells to
radiotherapy and reduced the side effects of the radia-
tion. The mechanism underlying the effects requires
further study.
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